These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12652459)

  • 1. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
    Hainsworth JD
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
    Hainsworth JD
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):25-9. PubMed ID: 11842385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.
    Hainsworth JD; Litchy S; Burris HA; Scullin DC; Corso SW; Yardley DA; Morrissey L; Greco FA
    J Clin Oncol; 2002 Oct; 20(20):4261-7. PubMed ID: 12377971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonging remission with rituximab maintenance therapy.
    Hainsworth JD
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):17-21. PubMed ID: 15042530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Litchy S; Barton JH; Houston GA; Hermann RC; Bradof JE; Greco FA;
    J Clin Oncol; 2003 May; 21(9):1746-51. PubMed ID: 12721250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
    Keating GM
    Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial.
    Hainsworth JD
    Semin Oncol; 2002 Feb; 29(1S2):25-29. PubMed ID: 28140088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
    Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
    Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Cvetković RS; Perry CM
    Drugs; 2006; 66(6):791-820. PubMed ID: 16706552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
    Leahy MF; Seymour JF; Hicks RJ; Turner JH
    J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
    Keating GM
    Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA
    J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatment approaches to indolent non-Hodgkin's lymphoma.
    Seymour JF
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):27-32. PubMed ID: 15042532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.
    Davis TA; White CA; Grillo-López AJ; Velásquez WS; Link B; Maloney DG; Dillman RO; Williams ME; Mohrbacher A; Weaver R; Dowden S; Levy R
    J Clin Oncol; 1999 Jun; 17(6):1851-7. PubMed ID: 10561225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.